Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway
By: Wei-Sheng Chen, Jun-Na Hou, Yu-Biao Guo, Hui-Ling Yang, Can-Mao Xie, Yong-Cheng Lin and Zhi-Gang She

Journal of Experimental & Clinical Cancer Research 2011, 30:17 doi:10.1186/1756-9966-30-17
Published: 8 February 2011

Abstract (Provisional)

Background

Bostrycin is a novel compound isolated from marine fungi that inhibits proliferation of many cancer cells. However, the inhibitory effect of bostrycin on lung cancers has not been reported. This study is to investigate the inhibitory effects and mechanism of bostrycin on human lung cancer cells in vitro.

Methods

We used MTT assay, flow cytometry, microarray, real time PCR, and Western blotting to detect the effect of bostrycin on A549 human pulmonary adenocarcinoma cells.

Results

We showed a significant inhibition of cell proliferation and induction of apoptosis in bostrycin-treated lung adenocarcinoma cells. Bostrycin treatment caused cell cycle arrest in the G0/G1 phase. We also found the upregulation of microRNA-638 and microRNA-923 in bostrycin-treated cells. further, we found the downregulation of p110 and p-Akt/PKB proteins and increased activity of p27 protein after bostrycin treatment in A549 cells.

Conclusions

Our study indicated that bostrycin had a significant inhibitory effect on proliferation of A549 cells. It is possible that upregulation of microRNA-638 and microRNA-923 and downregulaton of the PI3K/AKT pathway proteins played a role in induction of cell cycle arrest and apoptosis in bostrycin-treated cells.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements